Avacta Group (AVCT) H2 2024 earnings summary

Executive summary

• Transitioned to a pure-play oncology biopharmaceutical company, divesting diagnostics to focus on the proprietary precision peptide drug conjugate platform.

• Achieved clinical proof of concept for the platform, showing significant reduction in toxicities and efficacy in salivary gland cancer and soft tissue sarcoma.

• Lead clinical program FAPDOX (AVA6000) completed phase 1A and is enrolling phase 1B expansion cohorts in multiple solid tumor indications.

• Strategic collaboration with Tempus leverages AI for smarter clinical trial design and indication selection.

• Strengthened leadership team with new CFO, CSO, and non-executive directors.

Financial highlights

• R&D investment of £14.27M in 2023, in line with expectations for precision and therapeutic programs.

• Administrative expenses rose to £12.05M from £7.89M, mainly due to management changes and professional fees.

• Loss from continuing operations was £28.98M, nearly flat year-over-year.

• Operating cash outflow increased to £24.5M from £14.87M, reflecting higher R&D and one-off realignment costs.

• Cash and equivalents at Dec 31, 2024: £12.87M; at April 2025: £17.3M after diagnostics divestment, extending runway into Q1 2026.

Outlook and guidance

• Cash runway extends into Q1 2026; long-term funding strategy remains a top priority.

• FAPDOX expansion cohort data in salivary gland cancer expected late 2025; triple-negative breast cancer data in H1 2026.

• FAP-Exatecan IND filing and phase 1 trial start anticipated Q1 2026, with initial data by end of 2026.

• Third pipeline program candidate selection expected later in 2025, aiming for IND in late 2026.

• Ongoing business development and partnership discussions for both lead assets.